Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2013-11-01 Board/Management Inform…
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 30, 2013. The key content is the appointment of a new director, Mr. David W.J. McGirr, to the Board and as Chairman of the Audit Committee, and the resignation of Mr. Richard Kollender from the Board and as Chairman of the Audit Committee. The document details changes in the company's board of directors and senior management. There is no financial data, earnings information, or other report content. This fits the category of Board/Management Information (MANG). The document length is 5381 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is MANG with high confidence.
2013-11-01 English
4 Filing
Director's Dealing
2013-11-01 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 15, 2013. It reports an event under Item 8.01 "Other Events," specifically announcing the completion of patient enrollment for a clinical study. The document includes a press release as an exhibit. There are no financial statements, earnings data, or detailed financial analysis present. The document is short (3088 characters) and primarily serves as a current report to announce a specific event rather than a financial report or detailed management discussion. Therefore, it fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for filings that do not fit other specific categories.
2013-10-15 English
4 Filing
Director's Dealing
2013-10-04 English
SC 13G/A Filing
Major Shareholding Notification
2013-08-12 English
10-Q Filing
Interim / Quarterly Report Q2 2013
2013-08-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.